20 source-based articles maintained by the HealthRX.com Editorial Team.
Showing 20 of 20 clinical reviews.
A deep dive into how MK-677 (ibutamoren) affects appetite and food cravings, covering ghrelin mechanisms, clinical trial data, onset timing, and how to manage hunger side effects safely.
A guide to MK-677 (ibutamoren) in patients with autoimmune conditions. Covers GH/IGF-1 immune modulation, clinical trial data, risks, and practical management.
A clinician-level review of how MK-677 (ibutamoren) affects bone density, fracture risk, and skeletal remodeling, covering key trials, mechanisms, dosing, and safety signals.
A physician-level review of MK-677 (ibutamoren) cancer risk signals, covering IGF-1 biology, clinical trial data, preclinical findings, and practical safety guidance for patients and clinicians.
A deep-dive into MK-677 (ibutamoren) cardiovascular effects, covering fluid retention, blood pressure, insulin resistance, and what the longest human trials actually found.
A analysis of MK-677 (ibutamoren) and its effects on cognition, memory, and brain health, covering RCT data, GH/IGF-1 mechanisms, sleep quality research, and safety considerations for anyone evaluating this secretagogue.
A GRADE-level appraisal of every published MK-677 (ibutamoren) clinical trial: GH/IGF-1 endpoints, body composition, bone density, sleep, cognition, and safety, prepared for editorial and medical review.
A analysis of MK-677 (ibutamoren) and its effects on liver function, covering hepatotoxicity risk, ALT/AST changes, GH-IGF-1 signaling, and monitoring protocols based on primary literature.
A clinical review of how MK-677 (ibutamoren) affects mood, sleep, anxiety, and cognitive function, including trial data, mechanism of action, and what the current evidence does and does not support.
A analysis of how MK-677 (ibutamoren) affects metabolic rate, energy expenditure, GH/IGF-1 signaling, body composition, and insulin sensitivity, with citations from primary clinical trials.
A breakdown of MK-677 (ibutamoren) microdosing protocols, clinical trial data, GH/IGF-1 pharmacokinetics, and safety considerations for anyone researching this investigational GH secretagogue.
A deep dive into MK-677 (ibutamoren) muscle preservation strategies, covering mechanisms, trial data, dosing protocols, and safety considerations for clinicians and informed patients.
Why MK-677 stops working and how to fix it: a clinician-level guide to ibutamoren plateaus, desensitization, dosing errors, and lab-confirmed non-response with primary-literature support.
A guide to MK-677 rebound effects after stopping ibutamoren, covering GH/IGF-1 suppression, hunger spikes, fluid loss, and evidence-based tapering strategies.
A analysis of MK-677 (ibutamoren) and kidney function: does this GH secretagogue protect the renal system, pose risks, or neither? Primary-literature citations throughout.
A guide to how season, light exposure, temperature, and circadian biology interact with MK-677 (ibutamoren) dosing, timing, and expected outcomes throughout the year.
A analysis of how MK-677 (ibutamoren) affects sexual function, libido, and hormone levels, including clinical trial data, known mechanisms, and risks.
A analysis of how MK-677 (ibutamoren) affects sleep architecture, REM and slow-wave sleep duration, GH pulse timing, and what the clinical trial data mean for patients and clinicians.
A clinician-level guide to safely restarting MK-677 (ibutamoren) after acute illness, covering timing, dose re-titration, lab monitoring, contraindications, and the latest clinical evidence.
A week-by-week guide to MK-677 (ibutamoren) effects during the first month: GH/IGF-1 timelines, sleep changes, side effects, and clinical context, with clear notes on what is established versus anecdotal.